Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glenmark Pharmaceuticals Ltd. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Glenmark Pharmaceuticals Ltd. - Product Pipeline Review - 2016', provides an overview of the Glenmark Pharmaceuticals Ltd.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Glenmark Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Glenmark Pharmaceuticals Ltd. - The report provides overview of Glenmark Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Glenmark Pharmaceuticals Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Glenmark Pharmaceuticals Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Glenmark Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Glenmark Pharmaceuticals Ltd. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glenmark Pharmaceuticals Ltd.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Glenmark Pharmaceuticals Ltd. Snapshot 5 Glenmark Pharmaceuticals Ltd. Overview 5 Key Information 5 Key Facts 5 Glenmark Pharmaceuticals Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Glenmark Pharmaceuticals Ltd. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Glenmark Pharmaceuticals Ltd. - Pipeline Products Glance 13 Glenmark Pharmaceuticals Ltd. - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Glenmark Pharmaceuticals Ltd. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Glenmark Pharmaceuticals Ltd. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Glenmark Pharmaceuticals Ltd. - Drug Profiles 17 crofelemer DR 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 GSP-301 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 GBR-830 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 GRC-17536 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 GBR-1302 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 GBR-900 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 GRC-27864 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 GBR-1342 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 GBR-600 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecule to Antagonize TRPM8 for Neuropathic Pain 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Glenmark Pharmaceuticals Ltd. - Pipeline Analysis 29 Glenmark Pharmaceuticals Ltd. - Pipeline Products by Target 29 Glenmark Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 31 Glenmark Pharmaceuticals Ltd. - Pipeline Products by Molecule Type 32 Glenmark Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 33 Glenmark Pharmaceuticals Ltd. - Recent Pipeline Updates 35 Glenmark Pharmaceuticals Ltd. - Dormant Projects 40 Glenmark Pharmaceuticals Ltd. - Discontinued Pipeline Products 41 Discontinued Pipeline Product Profiles 41 GRC-15300 41 GRC-6211 41 oglemilast 41 revamilast 41 Glenmark Pharmaceuticals Ltd. - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46
List of Tables
Glenmark Pharmaceuticals Ltd., Key Information 5 Glenmark Pharmaceuticals Ltd., Key Facts 5 Glenmark Pharmaceuticals Ltd. - Pipeline by Indication, 2016 8 Glenmark Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016 9 Glenmark Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016 10 Glenmark Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2016 11 Glenmark Pharmaceuticals Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 12 Glenmark Pharmaceuticals Ltd. - Phase III, 2016 13 Glenmark Pharmaceuticals Ltd. - Phase II, 2016 14 Glenmark Pharmaceuticals Ltd. - Phase I, 2016 15 Glenmark Pharmaceuticals Ltd. - Preclinical, 2016 16 Glenmark Pharmaceuticals Ltd. - Pipeline by Target, 2016 30 Glenmark Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016 31 Glenmark Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016 32 Glenmark Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2016 34 Glenmark Pharmaceuticals Ltd. - Recent Pipeline Updates, 2016 35 Glenmark Pharmaceuticals Ltd. - Dormant Developmental Projects,2016 40 Glenmark Pharmaceuticals Ltd. - Discontinued Pipeline Products, 2016 41 Glenmark Pharmaceuticals Ltd., Subsidiaries 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
